Navigation Links
Scientists Discover Non-dietary Therapy For Celiac Diseases

Scientists from the Stanford University and the Celiac Sprue Research Foundation have claimed to discover a non-dietary remedy for the treatment of celiac sprue// that is an inherited inflammatory disorder of the small intestine that affects 1 in 200 people around the world. The two research studies that have been published in the June issue of Chemistry and Biology have opened the way for clinical testing with an oral enzyme therapy that could prevent various symptoms and complications of this widespread disease.

People with celiac sprue, also called celiac disease, cannot tolerate the protein gluten in their diet. Gluten is present in grains like wheat, barley, and rye. When gluten is ingested by a celiac patient, it sets off an inflammatory reaction that damages the small intestine, leading to malabsorption, an autoimmune-like response, and many other complications. The only effective therapy for celiac disease is complete dietary exclusion of gluten. However, the ubiquitous nature of gluten poses a constant threat to celiacs, and a majority of celiac patients who adopt a restrictive diet still exhibit structural and functional gut abnormalities.

"Non-dietary therapies that allow celiac patients to safely incorporate low-to-moderate levels of gluten into their daily diet would be of considerable benefit," explains study leader Dr. Chaitan Khosla, from Stanford University and. "Having demonstrated earlier that certain types of enzymes can detoxify gluten, our laboratory set out to devise an optimal oral enzyme therapy for celiac sprue by borrowing from nature. In germinating barley seed, gluten serves as a nutritious storage protein that is efficiently digested by enzymes. One enzyme, EP-B2, plays a crucial role in this process by breaking gluten proteins after glutamine residues, which comprise one-third of all amino acid residues in gluten."

Dr. Khosla's group used recombinant bacteria to produce a form of EP-B2 that only acti vates under acidic conditions similar to the conditions found in the human stomach. The researchers demonstrated that EP-B2 efficiently digested gluten protein under gastric conditions and, importantly, EP-B2 was most specific for those parts of gluten that are known to trigger celiac pathogenesis. In a second study, the researchers went on to devise an even more potent double enzyme therapy for detoxifying gluten.

EP-B2 was tested in combination with another well-characterized enzyme called PEP that breaks gluten protein after proline residues. Like glutamine, proline is also abundant in inflammatory gluten peptides. At very high gluten loads, where neither PEP nor EP-B2 alone could detoxify gluten quickly enough to prevent inflammation, a PEP and EP-B2 combination completely abolished gluten immunotoxicity within ten minutes under simulated gastric and duodenal conditions.

In this tag-team therapy, EP-B2 first cleaved gluten into small pieces under gastric conditions that were then easier for PEP to fully detoxify under duodenal conditions. "Our results suggest that recombinant EP-B2 should be effective as supportive therapy to help celiacs cope with the 'hidden' gluten in everyday life, and that a two-enzyme cocktail containing PEP and EP-B2 may even allow celiacs to resume a more normal diet in the future," offers Dr. Khosla.

Source: EurekAlert
'"/>




Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... T.E.N., ... that nominations will be accepted February 8, 2016 through May 8, 2016 ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth ... incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher ... make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... The AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago ... about helpful interventions and causes of chronic illness in children. , Very recent articles ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... added Kybella® to his medical and surgical expertise. Technically known as deoxycholic acid ... medication used as a non-surgical alternative for reduction of fat below the chin ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 Vestagen Technical Textiles, ... performance apparel for healthcare and other demanding applications, today ... Executive Officer. He replaces Dale Pfost , PhD, ... Mr. Bold is also joining Vestagen,s Board of Directors. ... class of active barrier technologies that combines fluid repellent, ...
(Date:2/8/2016)... RICHMOND, Calif. , Feb. 8, 2016 /PRNewswire/ ... leader in therapeutic genome editing, announced that the ... the Company,s Investigational New Drug (IND) application for ... a life-long therapy for Mucopolysaccharidosis Type I (MPS ... and enables Sangamo to initiate a Phase 1/2 ...
(Date:2/5/2016)... , Feb. 5, 2016  Despite the recent explosion ... than other industries to embrace Big Data due to ... On the medical side, organizations have begun looking to ... clinical trials to adherence. --> ... firm Best Practices, LLC, Big Data has started informing ...
Breaking Medicine Technology: